Panelists discuss clinical strategies to improve RSV vaccine uptake in high-risk adults by reviewing disease severity, comparing approved vaccines, and emphasizing the pharmacist’s pivotal role in patient education and vaccine advocacy to overcome hesitancy and increase protection in vulnerable populations.
An expert discusses how achieving molecular and clinical milestones early in chronic myeloid leukemia (CML) treatment reduces transformation risk, enables potential treatment discontinuation after specific criteria are met, and helps identify treatment resistance requiring mutational analysis or adherence assessment.
An expert discusses how pharmacists can overcome common vaccination barriers by addressing misconceptions about vaccine necessity, making strong provider recommendations, and educating patients about mild adverse effects while building trust through consistent communication.
An expert discusses how landmark trials such as ASC4FIRST, ENESTnd, and BFORE provide evidence for frontline tyrosine kinase inhibitor (TKI) selection, with asciminib showing superior tolerability and lower discontinuation rates (4.5%) compared with first-generation (11%) and second-generation TKIs (9.8%).
An expert discusses how pharmacists can evaluate patients with prior adverse vaccine reactions by distinguishing between mild local reactions and serious anaphylactic responses, then recommending supervised vaccination or medical center administration when appropriate.
Understanding RSV’s impact on respiratory and cardiovascular health underscores the importance of holistic management, prevention through vaccination, and continued innovation in treatment strategies.
Experts discussed the promising future of pericarditis treatment.
Panelists discuss how the long-term management of movement disorders like tardive dyskinesia, Parkinson disease, and Huntington disease requires individualized, patient-centered care that adapts to changing health and tolerance over time, aiming to maintain function and quality of life despite differing disease trajectories and treatment challenges.
Panelists discuss how open-label extension studies of VMAT2 inhibitors demonstrate sustained efficacy, tolerability, and patient retention in long-term treatment of tardive dyskinesia—including in older adults—highlighting their potential to improve quality of life despite manageable adverse effects.
Prescription digital therapeutics (PDTs) offer scalable, accessible alternatives to traditional treatments—supporting patients, providers, and payers while addressing gaps in mental health care.
LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA, discusses the new outpatient transplant program at Atrium Health Wake Forest Baptist in North Carolina.
Expert explores the expanding role of FDA-approved Prescription Digital Therapeutics (PDTs).
An expert discusses the challenges of diagnosing and treating RSV in older adults and highlights the critical role of prevention.
An expert discusses how pharmacists should follow CDC immunization schedules for different age groups and use shared clinical decision-making for patients with prior vaccination history, while considering contraindications primarily related to severe allergic reactions to vaccine components.
An expert discusses how the 5 FDA-approved pneumococcal vaccines differ, with newer conjugate vaccines like PCV20 and PCV21 offering broader serotype coverage and better immune memory compared with the older polysaccharide vaccine, though geographic factors may influence vaccine selection.
Pharmacy leaders from Cone Health discuss how robotic compounding technologies have improved safety, accuracy, and reliability in hazardous and sterile medication preparation across oncology and acute care settings.
LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA, discusses the new outpatient transplant program at Atrium Health Wake Forest Baptist in North Carolina.
Manish Agrawal, MD, discusses the implementation of psilocybin-assisted therapy in a community cancer setting, highlighting its potential to provide sustained relief from depression and anxiety and its significant efficacy advantage over selective serotonin reuptake inhibitors for patients with cancer.
Courtney Cavalieri, PharmD, BCOP; and Kenneth Tham, PharmD, BCOP, discuss how pharmacists play a crucial role in managing patients with biliary tract cancer by providing expertise on biomarker testing, treatment selection between targeted therapies like FGFR and HER2 inhibitors, developing monitoring protocols for unique toxicities such as hyperphosphatemia, and educating patients on adverse effect management to optimize treatment outcomes in this rare cancer type.
Gianni Scappaticci, PharmD, BCOP, outlines a personalized, evidence-based approach to managing steroid-refractory chronic graft-versus-host disease (cGVHD) in a post–haploidentical transplant patient, highlighting the rationale for using ruxolitinib, belumosudil, or their combination based on disease progression and fibrotic features.
Pharmacists and clinicians collaborate to carefully manage rilonacept therapy.
Gianni Scappaticci, PharmD, BCOP, discusses key considerations in therapy selection, limitations of current treatments, and the evolving role of pharmacists in managing chronic graft-vs-host disease (cGVHD) through patient education, adherence support, and integration of emerging therapies.
An expert discusses how pharmacists can identify high-risk patients for pneumococcal disease by reviewing medication profiles for immunosuppressants and using electronic medical record vaccine tracking tools, while emphasizing that vulnerable populations face higher morbidity, mortality, and hospitalization rates compared with healthy individuals.
Panelists discuss how the use of both clinician- and patient-reported scales—such as the Impact TD scale, TDIS, and Impact TD Pro—enhances understanding of tardive dyskinesia’s true impact on daily functioning and quality of life, emphasizing the importance of incorporating patient perspectives to guide early, personalized treatment strategies that improve physical symptoms and overall well-being.
Panelists discuss how tardive dyskinesia in older adults often goes unrecognized due to symptom overlap with normal aging, underscoring the importance of early screening, timely intervention with evidence-based treatments like VMAT2 inhibitors, and a multidisciplinary approach to preserve function, independence, and mental well-being.
An expert discusses how pneumococcal disease presents differently across age groups, with children primarily experiencing ear infections, whereas adults face more serious, invasive complications such as bacteremia and meningitis, though vaccination efforts have significantly reduced overall incidence rates.
An expert discusses how different tyrosine kinase inhibitor (TKI) mechanisms of action, including asciminib’s allosteric binding vs traditional ATP-competitive inhibitors, influence treatment selection based on off-target effects and adverse effect profiles, with patients with advanced-phase chronic myeloid leukemia (CML) requiring second-generation or higher TKIs for faster response rates.
An expert discusses how National Comprehensive Cancer Network (NCCN) guidelines recommend first-line chronic myeloid leukemia (CML) treatments, including imatinib, nilotinib, and newer agents, emphasizing the importance of close monitoring through weekly laboratory tests and quantitative polymerase chain reaction testing to track BCR::ABL1 transcript levels and ensure patients meet critical milestones at 3, 6, and 12 months.
